Movement Disorders

Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 1, 2025.

New trial data reveals ATH434 significantly improves symptoms and biomarkers in multiple system atrophy patients, paving the way for potential treatment advancements.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 25, 2025.

A recent study uncovered existing medications that may lower mortality risk in patients with Parkinson disease, suggesting potential for repurposing in future trials.

Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.

Findings from a recently published study may offer clinicians a deeper understanding of the complex relationship between Parkinson disease biology and social or environmental factors.

Here's some of what is coming soon to NeurologyLive® this week.

Findings revealed that dry mouth and falls were reported more frequently in patients with Parkinson disease treated with solifenacin in comparison with pelvic floor muscle exercise-based behavioral therapy.

Neurology News Network. for the week ending July 19, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 18, 2025.

Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

A study links high ultraprocessed food consumption to increased risks of nonmotor Parkinson's disease symptoms, highlighting potential dietary impacts on neurodegeneration.

Nuri Jacoby, MD, a neurologist at Maimonides Medical Center and SUNY Downstate, previewed his talk at the 2025 AUPN Annual Meeting on using simulation to evaluate nonclinical competencies like communication and professionalism. [WATCH TIME: 3 minutes]

The professor of neurological surgery at Weill Cornell Medicine shared his reaction to the recent approval of the Exablate Neuro platform that uses MRI-guided focused ultrasound to treat Parkinson disease. [WATCH TIME: 5 minutes]

A groundbreaking trial reveals that subthalamic deep brain stimulation effectively treats isolated dystonia, showing significant long-term motor and mental health improvements.

The movement disorder specialist and patient living with Parkinson disease highlighted the need for a more human-centered approach in managing chronic and progressive movement disorders. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 11, 2025.

The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. [WATCH TIME: 5 minutes]

A recent study confirmed ambroxol's safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.

The assistant professor of medicine at Stanford University highlighted how gastrointestinal dysfunction in Parkinson disease can affect levodopa bioavailability and symptom management. [WATCH TIME: 7 minutes]

Exablate Neuro is a noninvasive, MRI-guided focused ultrasound technology designed to treat targeted brain areas without incisions or implanted hardware, offering a lower-risk alternative to traditional surgery.

The director of movement disorders at the Banner Sun Health Research Institute discussed distinguishing atypical Parkinsonian disorders early and planning care around their complex symptomatology. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.